🇺🇸 FDA

Drug profile · INN

obiltoxaximab

NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)

approved J06BB22
US status
approved
Patents linked
0
News articles
0

Quick answer

obiltoxaximab (NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN obiltoxaximab
Brand NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)
Route INJECTION
Formulation INJECTABLE
ATC code J06BB22

Frequently asked questions

What is obiltoxaximab?

obiltoxaximab (NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL)) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for obiltoxaximab?

NYXTHRACIS (PREVIOUSLY OBILTOXAXIMAB SFL) is a marketed brand name for obiltoxaximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of obiltoxaximab?

obiltoxaximab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.